Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1, demonstrating sustained safety and efficacy profiles in managing recurrent or metastatic cervical cancer. This therapeutic antibody shows promising potential in treating additional oncological indications, including small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma. Its mechanism involves the inhibition of the PD-1/PD-L1 pathway, a critical axis in tumor immune evasion, thereby enhancing anti-tumor immune responses. Socazolimab is under investigation for its versatility and effectiveness across a broad spectrum of cancer types.
Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1, demonstrating sustained safety and efficacy profiles in managing recurrent or metastatic cervical cancer. This therapeutic antibody shows promising potential in treating additional oncological indications, including small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma. Its mechanism involves the inhibition of the PD-1/PD-L1 pathway, a critical axis in tumor immune evasion, thereby enhancing anti-tumor immune responses. Socazolimab is under investigation for its versatility and effectiveness across a broad spectrum of cancer types.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
